Osteoporosis

Study reveals facts about how osteoporosis therapies affect bone cell activity

Published in Drug Week, September 9th, 2005

A new study comparing the head-to-head effects of teriparatide [rDNA origin] injection, (20 mcg), marketed in the U.S. as Forteo, and Fosamax (10 mg alendronate sodium), gives new information on how the two osteoporosis therapies affect bone cell activity.

Forteo is the first and only U.S. Food and Drug Administration (FDA) approved bone formation agent that actually forms new bone in postmenopausal women with osteoporosis at high risk for fracture. Fosamax is an inhibitor of bone resorption. These data were published in Archives of Internal Medicine.

The study, which provides more in-depth information than previously available about these two...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Week

Source: Drug Week (2005-09-09)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry